1. The above financial results were reviewed by Audit Committee on June 29, 2009 and taken on record by the Board in its meeting held on June 30, 2009.

2. The Consolidated results include the results of wholly owned subsidiary of the Company - M/s. Chempharma Pvt Ltd registered in Sri Lanka.

3. The Company is exclusively in the pharmaceutical business segment.

4. The Board of Directors has recommended the Final Dividend of Re 0.10/- per equity share (10% on the face value of Re 1/- per equity share) to the Members of the Company, out of profits of the Company for the financial year 2008-09.

5. Consequent to the notification, issued by the Ministry of Corporate Affairs, amending the Accounting Standard (AS) 11 - the Effect of Changes in Foreign Exchange Rates, the exchange differences on foreign currency denominated long term borrowings relating to the acquisition of depreciable capital assets are adjusted in the carrying cost of such assets for current year. Exchange differences pertaining to financial year 2007-08 previously recognised in profit & loss account reversed to General Reserve by adjusting the carrying cost of fixed assets.

Sanjiv Goyal
Chairman & Managing Director